![PDF) Safety of Ovaleap® compared to Gonal-f® in real-world clinical practice: results from the safety of ovaleap follitropin alfa (SOFIA) study PDF) Safety of Ovaleap® compared to Gonal-f® in real-world clinical practice: results from the safety of ovaleap follitropin alfa (SOFIA) study](https://i1.rgstatic.net/publication/350438778_Safety_of_OvaleapR_compared_to_Gonal-fR_in_real-world_clinical_practice_results_from_the_safety_of_ovaleap_follitropin_alfa_SOFIA_study/links/605f393b92851cd8ce6f9f4f/largepreview.png)
PDF) Safety of Ovaleap® compared to Gonal-f® in real-world clinical practice: results from the safety of ovaleap follitropin alfa (SOFIA) study
![OVALEAP (follitropine alfa) : nouveau biosimilaire de GONALF dans la prise en charge de l'infertilité OVALEAP (follitropine alfa) : nouveau biosimilaire de GONALF dans la prise en charge de l'infertilité](https://vidalactus.vidal.fr/files/uploads/actus/images/OVALEAP_GONAL_F_follitropine-alfa_infertilite_anovulation_superovulation_assistance_medical_procreation_spermatogenese_hypogonadisme_hypogonadotrophique_biosimilaire_TEVAsante.jpg)
OVALEAP (follitropine alfa) : nouveau biosimilaire de GONALF dans la prise en charge de l'infertilité
![PDF) Manufacturing of Recombinant Human Follicle-Stimulating Hormone Ovaleap(®) (XM17), Comparability with Gonal-f(®), and Performance/Consistency PDF) Manufacturing of Recombinant Human Follicle-Stimulating Hormone Ovaleap(®) (XM17), Comparability with Gonal-f(®), and Performance/Consistency](https://i1.rgstatic.net/publication/315827471_Manufacturing_of_Recombinant_Human_Follicle-Stimulating_Hormone_OvaleapR_XM17_Comparability_with_Gonal-fR_and_PerformanceConsistency/links/58ed3090aca2724f0a26c1c8/largepreview.png)
PDF) Manufacturing of Recombinant Human Follicle-Stimulating Hormone Ovaleap(®) (XM17), Comparability with Gonal-f(®), and Performance/Consistency
![Teva completes $703M sale of women's health products to CVC Capital Partners. - Philadelphia Business Journal Teva completes $703M sale of women's health products to CVC Capital Partners. - Philadelphia Business Journal](https://media.bizj.us/view/img/10777492/47002105ovaleap300ie-0-5ml*660xx640-360-0-60.jpg)
Teva completes $703M sale of women's health products to CVC Capital Partners. - Philadelphia Business Journal
![Teva completes $703M sale of women's health products to CVC Capital Partners. - Philadelphia Business Journal Teva completes $703M sale of women's health products to CVC Capital Partners. - Philadelphia Business Journal](https://media.bizj.us/view/img/2625011/doctor-patient-consult*1200xx1414-1414-354-0.jpg)